RLMD

Rating neutralAI Memo

Relmada Therapeutics

As of 2026-09-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

NDV-01 IND filing and potential Phase 3 RESCUE initiation • 2026-12-31

Base target: $4 / p=45% prob

Biggest risk

The expected NDV-01 timeline moved from mid-2026 in the May update to year-end 2026 in August, with GMP manufacturing and stability work still gating the IND [#SEC-8K-2026-05-12] [#SEC-8K-2026-08-06]. The investment case remains binary and execution-sensitive.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Encouraging NDV-01 Phase 2 results included a 95% complete-response rate at any time and 76% durable response at 12 months, while the balance sheet is positioned to support the planned program [#SEC-8K-2026-05-12] [#SEC-8K-2026-08-06].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-03

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NDV-01 manufacturing execution remains the near-term gate
Cash runway supports the planned development program
Encouraging NDV-01 Phase 2 results included a 95% complete-response rate at any time and 76% durable response at 12 months, while the balance sheet is positioned to support the planned program [#SEC-8K-2026-05-12] [#SEC-8K-2026-08-06].

BearKey bullets

Clinical and regulatory outcomes for NDV-01 and sepranolone remain binary and unproven.
Further GMP manufacturing or stability delays could postpone the NDV-01 IND and Phase 3 program.
Longer-term capital needs could increase if development scope expands beyond the current runway plan.

WatchKey bullets

NDV-01 IND filing and potential Phase 3 RESCUE initiation

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $4 (p=45%)

Target spread vs base: +73% / -35%

Scenario probabilities

Bull Target: $7 (p=25%)Base Target: $4 (p=45%)Bear Target: $3 (p=30%)

Commentary

Sentiment is cautious and event-driven. Primary filings support meaningful pipeline progress and cash runway, but the NDV-01 timeline has slipped and manufacturing remains the key gate [#SEC-8K-2026-05-12] [#SEC-8K-2026-08-06]. Coverage is low, social data and analyst-revision data are unavailable, and the deterministic prior is negative; treat the stock as a monitoring situation rather than a high-conviction bullish setup.

As of 2026-09-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

NDV-01 manufacturing execution remains the near-term gate
Cash runway supports the planned development program

Scenarios

Bull Target (Scenario probability)

$7 / p=25% prob

Base Target (Scenario probability)

$4 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
NDV-01 IND filing and potential Phase 3 RESCUE initiation
The company expects to file the NDV-01 IND by year-end 2026 and initiate the Phase 3 RESCUE registrational program after clearance, with clinical sites prepared for enrollment [#SEC-8K-2026-08-06].
Prob 55.00% • Move 28.00% • Priced-in 45.00%
EVENT2026-12-31
Sepranolone IND milestone in Prader-Willi syndrome
Relmada expects a sepranolone IND filing by year-end 2026 and a Phase 2 proof-of-concept study after clearance [#SEC-8K-2026-08-06].
Prob 50.00% • Move 12.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

NDV-01 manufacturing execution remains the near-term gate
2026-12-31
Relmada says GMP manufacturing and CMC work for NDV-01 are underway, with manufacturing execution required before the planned IND filing [#SEC-8K-2026-08-06]. Completion would reduce the principal near-term execution overhang; further slippage would pressure sentiment.
Prob 65% • Move 15% • Priced-in 50%

Long-term Catalysts

Months to a year

Cash runway supports the planned development program
2029-12-31
Relmada reported $217.7 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which management expects to fund operations through 2029, including the NDV-01 Phase 3 program [#SEC-8K-2026-08-06].
Prob 75% • Move 10% • Priced-in 60%

Risks

Clinical and regulatory outcomes for NDV-01 and sepranolone remain binary and unproven.
Further GMP manufacturing or stability delays could postpone the NDV-01 IND and Phase 3 program.
Longer-term capital needs could increase if development scope expands beyond the current runway plan.
The timing of additional NDV-01 data disclosure is not clearly established in the stored earnings context.

Peers

Symbol	Summary
CABA	Loose same-sector, similar-market-cap biotech comparator; not indication matched, so valuation comparison is limited.
CCCC	Loose small-cap biotech comparator with milestone-driven rather than commercial-earnings valuation; direct comparability is limited.
ENTX	Similar-market-cap life-sciences comparator, but its program mix and development path are not directly comparable to RLMD.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-03

Loading AI feed…

Symbol

Summary

CABA

Loose same-sector, similar-market-cap biotech comparator; not indication matched, so valuation comparison is limited.

CCCC

Loose small-cap biotech comparator with milestone-driven rather than commercial-earnings valuation; direct comparability is limited.

ENTX

Similar-market-cap life-sciences comparator, but its program mix and development path are not directly comparable to RLMD.